Astigmatism – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Astigmatism Market Outlook

Thelansis’s “Astigmatism Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Astigmatism treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Astigmatism Overview

Astigmatism, a prevalent refractive error, is characterized by alterations in the refraction of light in different eye meridians. This condition results in the failure of parallel rays of light passing through the cornea to converge on the retina at a single focal point. Astigmatism can manifest as either regular or irregular. Typical symptoms include asthenopia, discomfort, blurred and defective vision, elongation of objects, and difficulties with accommodation. Signs of astigmatism include partial lid closure, head tilt, vertically oval or tilted optic disc, and varying power in different meridians. The underlying causes of astigmatism can be attributed to corneal, lenticular, or retinal factors. Regular astigmatism can further be classified into "with the rule" astigmatism, "against the rule" astigmatism, oblique astigmatism, and bi-oblique astigmatism. The principles of Sturm's conoid elucidate the optics of regular astigmatism. In regular astigmatism cases, parallel light rays converge into two focal lines rather than focusing on a singular point. The arrangement of rays refracted through the toric surface is known as Sturm's conoid, and the distance between these lines is referred to as the focal interval of Sturm. Infants and neonates tend to exhibit higher degrees of astigmatism. Approximately 40 percent of newborns have around 1 diopter of astigmatism at birth, which typically diminishes to adult levels by one year due to normal eye maturation and globe remodeling. Treatment for regular astigmatism typically involves prescribing spectacles with cylindrical lenses that are determined after accurate refraction. Another option for correcting astigmatism is using rigid contact lenses, which can correct up to 2-3 diopters of astigmatism. Toric contact lenses are recommended for astigmatism exceeding this range. The prognosis for individuals with astigmatism is generally favorable if treated promptly, as there are several options for correction. Failure to treat astigmatism, particularly during childhood, can permanently reduce visual acuity and the development of amblyopia. It is important to note that astigmatism may change over time, necessitating new glasses and contact lenses. Refractive correction often successfully eliminates or reduces astigmatism in most cases. Individuals with keratoconus risk experiencing a decline in visual acuity due to high astigmatism, underscoring the need for timely and regular screenings.

• The prevalence of astigmatism in the general population varied from 7.6% to 61.7%, with higher rates in older individuals (≥70 years). The prevalence of with-the-rule astigmatism was higher in the younger population (≤40 years), while rates of against-the-rule and oblique astigmatism increased with age.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: